Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Bortezomib is active in mantle cell lymphoma (MCL), with approval in upfront and relapsed settings. Given inevitable recurrence following induction chemoimmunotherapy, maintenance approaches are a rational strategy to improve clinical outcomes. We conducted a phase II study to evaluate the safety an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Haematol
Hauptverfasser: Till, Brian G., Li, Hongli, Bernstein, Steven H., Fisher, Richard I., Burack, W. Richard, Rimsza, Lisa M., Floyd, Justin D., DaSilva, Marco A., Moore, Dennis F., Pozdnyakova, Olga, Smith, Sonali M., LeBlanc, Michael, Friedberg, Jonathan W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4710555/
https://ncbi.nlm.nih.gov/pubmed/26492567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13818
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge